|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase, immune system
|
 |
|
Title:
|
 |
Camelid vhh domain in complex with porcine pancreatic alpha- amylase
|
|
Structure:
|
 |
Alpha-amylase, pancreatic. Chain: a, b, c, d. Synonym: 1,4-alpha-d-glucan glucanohydrolase. Antibody vhh fragment cabamd9. Chain: e, f, g, h. Engineered: yes
|
|
Source:
|
 |
Sus scrofa. Pig. Organism_taxid: 9823. Other_details: pancreatic enzyme. Camelus dromedarius. Arabian camel. Organism_taxid: 9838. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Biol. unit:
|
 |
Dimer (from
)
|
|
Resolution:
|
 |
|
1.60Å
|
R-factor:
|
0.197
|
R-free:
|
0.219
|
|
|
Authors:
|
 |
A.Desmyter,S.Spinelli,F.Payan,M.Lauwereys,L.Wyns, S.Muyldermans,C.Cambillau
|
Key ref:
|
 |
A.Desmyter
et al.
(2002).
Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology.
J Biol Chem,
277,
23645-23650.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
01-Feb-02
|
Release date:
|
19-Jun-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, B, C, D:
E.C.3.2.1.1
- Alpha-amylase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Endohydrolysis of 1,4-alpha-glucosidic linkages in oligosaccharides and polysaccharides.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
extracellular region
|
2 terms
|
 |
|
Biological process
|
metabolic process
|
3 terms
|
 |
|
Biochemical function
|
catalytic activity
|
8 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Biol Chem
277:23645-23650
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology.
|
|
A.Desmyter,
S.Spinelli,
F.Payan,
M.Lauwereys,
L.Wyns,
S.Muyldermans,
C.Cambillau.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Camelids produce functional antibodies devoid of light chains and CH1 domains.
The antigen-binding fragment of such heavy chain antibodies is therefore
comprised in one single domain, the camelid heavy chain antibody VH (VHH). Here
we report on the structures of three dromedary VHH domains in complex with
porcine pancreatic alpha-amylase. Two VHHs bound outside the catalytic site and
did not inhibit or inhibited only partially the amylase activity. The third one,
AMD9, interacted with the active site crevice and was a strong amylase inhibitor
(K(i) = 10 nm). In contrast with complexes of other proteinaceous amylase
inhibitors, amylase kept its native structure. The water-accessible surface
areas of VHHs covered by amylase ranged between 850 and 1150 A(2), values
similar to or even larger than those observed in the complexes between proteins
and classical antibodies. These values could certainly be reached because a
surprisingly high extent of framework residues are involved in the interactions
of VHHs with amylase. The framework residues that participate in the antigen
recognition represented 25-40% of the buried surface. The inhibitory interaction
of AMD9 involved mainly its complementarity-determining region (CDR) 2 loop,
whereas the CDR3 loop was small and certainly did not protrude as it does in
cAb-Lys3, a VHH-inhibiting lysozyme. AMD9 inhibited amylase, although it was
outside the direct reach of the catalytic residues; therefore it is to be
expected that inhibiting VHHs might also be elicited against proteases. These
results illustrate the versatility and efficiency of VHH domains as protein
binders and enzyme inhibitors and are arguments in favor of their use as drugs
against diabetes.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. Sequences and three-dimensional structures of the
three VHHs. The three CDRs (1-3) are colored red, green, and
blue, respectively, and the cysteines are purple. A, anti-PPA
AMB7, AMD9, and AMD10 VHH amino acid sequences. The numbering is
according to Kabat ( 30). B, from left to right, views of the
AMB7, AMD9, and AMD10 VHHs in the same orientation with the CDR3
oriented in front (view made with SPOCK (33)).
|
 |
Figure 2.
Fig. 2. Views of the three VHHs superimposed on PPA with
the acarbose molecule bound (pink). The PPA surface is in gray,
and its visible catalytic residue Asp-300 is in red. The C trace of
the VHHs is orange, the three CDRs (1-3) are colored red, green,
and blue, respectively, and each VHH surface is transparent.
Inset, close-up view of the PPA active site with the inhibitory
AMD9 VHH bound. The saccharidic inhibitor acarbose has been
positioned in the active site according to the x-ray structure
as a probe of the saccharide position. Two residues of the VHH,
Tyr-52 and Arg-52a (CPK yellow and orange), clash with the
modeled acarbose (views made with SPOCK (33)).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2002,
277,
23645-23650)
copyright 2002.
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
F.Rahbarizadeh,
D.Ahmadvand,
and
Z.Sharifzadeh
(2011).
Nanobody; an old concept and new vehicle for immunotargeting.
|
| |
Immunol Invest, 40,
299-338.
|
 |
|
|
|
|
 |
M.Wu,
Y.J.Park,
E.Pardon,
S.Turley,
A.Hayhurst,
J.Deng,
J.Steyaert,
and
W.G.Hol
(2011).
Structures of a key interaction protein from the Trypanosoma brucei editosome in complex with single domain antibodies.
|
| |
J Struct Biol, 174,
124-136.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
Y.Koldobskaya,
E.M.Duguid,
D.M.Shechner,
N.B.Suslov,
J.Ye,
S.S.Sidhu,
D.P.Bartel,
S.Koide,
A.A.Kossiakoff,
and
J.A.Piccirilli
(2011).
A portable RNA sequence whose recognition by a synthetic antibody facilitates structural determination.
|
| |
Nat Struct Mol Biol, 18,
100-106.
|
 |
|
|
|
|
 |
A.Kirchhofer,
J.Helma,
K.Schmidthals,
C.Frauer,
S.Cui,
A.Karcher,
M.Pellis,
S.Muyldermans,
C.S.Casas-Delucchi,
M.C.Cardoso,
H.Leonhardt,
K.P.Hopfner,
and
U.Rothbauer
(2010).
Modulation of protein properties in living cells using nanobodies.
|
| |
Nat Struct Mol Biol, 17,
133-138.
|
 |
|
|
|
|
 |
J.Janin
(2010).
Protein-protein docking tested in blind predictions: the CAPRI experiment.
|
| |
Mol Biosyst, 6,
2351-2362.
|
 |
|
|
|
|
 |
K.Conrath,
A.S.Pereira,
C.E.Martins,
C.G.Timóteo,
P.Tavares,
S.Spinelli,
J.Kinne,
C.Flaudrops,
C.Cambillau,
S.Muyldermans,
I.Moura,
J.J.Moura,
M.Tegoni,
and
A.Desmyter
(2009).
Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductase.
|
| |
Protein Sci, 18,
619-628.
|
 |
|
|
|
|
 |
K.V.Korotkov,
E.Pardon,
J.Steyaert,
and
W.G.Hol
(2009).
Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody.
|
| |
Structure, 17,
255-265.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Kowalsman,
and
M.Eisenstein
(2009).
Combining interface core and whole interface descriptors in postscan processing of protein-protein docking models.
|
| |
Proteins, 77,
297-318.
|
 |
|
|
|
|
 |
D.P.Simmons,
V.A.Streltsov,
O.Dolezal,
P.J.Hudson,
A.M.Coley,
M.Foley,
D.F.Proll,
and
S.D.Nuttall
(2008).
Shark IgNAR antibody mimotopes target a murine immunoglobulin through extended CDR3 loop structures.
|
| |
Proteins, 71,
119-130.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.Ratier,
M.Urrutia,
G.Paris,
L.Zarebski,
A.C.Frasch,
and
F.A.Goldbaum
(2008).
Relevance of the diversity among members of the Trypanosoma cruzi trans-sialidase family analyzed with camelids single-domain antibodies.
|
| |
PLoS ONE, 3,
e3524.
|
 |
|
|
|
|
 |
J.Mintseris,
B.Pierce,
K.Wiehe,
R.Anderson,
R.Chen,
and
Z.Weng
(2007).
Integrating statistical pair potentials into protein complex prediction.
|
| |
Proteins, 69,
511-520.
|
 |
|
|
|
|
 |
V.Lafont,
M.Schaefer,
R.H.Stote,
D.Altschuh,
and
A.Dejaegere
(2007).
Protein-protein recognition and interaction hot spots in an antigen-antibody complex: free energy decomposition identifies "efficient amino acids".
|
| |
Proteins, 67,
418-434.
|
 |
|
|
|
|
 |
W.S.Jong,
C.M.ten Hagen-Jongman,
T.den Blaauwen,
D.J.Slotboom,
J.R.Tame,
D.Wickström,
J.W.de Gier,
B.R.Otto,
and
J.Luirink
(2007).
Limited tolerance towards folded elements during secretion of the autotransporter Hbp.
|
| |
Mol Microbiol, 63,
1524-1536.
|
 |
|
|
|
|
 |
A.J.Groot,
P.Verheesen,
E.J.Westerlaken,
E.H.Gort,
P.van der Groep,
N.Bovenschen,
E.van der Wall,
P.J.van Diest,
and
A.Shvarts
(2006).
Identification by phage display of single-domain antibody fragments specific for the ODD domain in hypoxia-inducible factor 1alpha.
|
| |
Lab Invest, 86,
345-356.
|
 |
|
|
|
|
 |
D.M.Tremblay,
M.Tegoni,
S.Spinelli,
V.Campanacci,
S.Blangy,
C.Huyghe,
A.Desmyter,
S.Labrie,
S.Moineau,
and
C.Cambillau
(2006).
Receptor-binding protein of Lactococcus lactis phages: identification and characterization of the saccharide receptor-binding site.
|
| |
J Bacteriol, 188,
2400-2410.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.De Genst,
K.Silence,
K.Decanniere,
K.Conrath,
R.Loris,
J.Kinne,
S.Muyldermans,
and
L.Wyns
(2006).
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.
|
| |
Proc Natl Acad Sci U S A, 103,
4586-4591.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Spinelli,
A.Desmyter,
C.T.Verrips,
H.J.de Haard,
S.Moineau,
and
C.Cambillau
(2006).
Lactococcal bacteriophage p2 receptor-binding protein structure suggests a common ancestor gene with bacterial and mammalian viruses.
|
| |
Nat Struct Mol Biol, 13,
85-89.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.Law,
M.Hotchko,
and
L.Ten Eyck
(2005).
Progress in computation and amide hydrogen exchange for prediction of protein-protein complexes.
|
| |
Proteins, 60,
302-307.
|
 |
|
|
|
|
 |
H.Revets,
P.De Baetselier,
and
S.Muyldermans
(2005).
Nanobodies as novel agents for cancer therapy.
|
| |
Expert Opin Biol Ther, 5,
111-124.
|
 |
|
|
|
|
 |
J.Janin
(2005).
Assessing predictions of protein-protein interaction: the CAPRI experiment.
|
| |
Protein Sci, 14,
278-283.
|
 |
|
|
|
|
 |
L.Dolecková-Maresová,
M.Pavlík,
M.Horn,
and
M.Mares
(2005).
De novo design of alpha-amylase inhibitor: a small linear mimetic of macromolecular proteinaceous ligands.
|
| |
Chem Biol, 12,
1349-1357.
|
 |
|
|
|
|
 |
M.Arbabi-Ghahroudi,
J.Tanha,
and
R.MacKenzie
(2005).
Prokaryotic expression of antibodies.
|
| |
Cancer Metastasis Rev, 24,
501-519.
|
 |
|
|
|
|
 |
N.Pohl
(2005).
Acyclic peptide inhibitors of amylases.
|
| |
Chem Biol, 12,
1257-1258.
|
 |
|
|
|
|
 |
P.Carter,
V.I.Lesk,
S.A.Islam,
and
M.J.Sternberg
(2005).
Protein-protein docking using 3D-Dock in rounds 3, 4, and 5 of CAPRI.
|
| |
Proteins, 60,
281-288.
|
 |
|
|
|
|
 |
S.C.Dias,
O.L.Franco,
C.P.Magalhães,
O.B.de Oliveira-Neto,
R.A.Laumann,
E.L.Figueira,
F.R.Melo,
and
M.F.Grossi-De-Sá
(2005).
Molecular cloning and expression of an alpha-amylase inhibitor from rye with potential for controlling insect pests.
|
| |
Protein J, 24,
113-123.
|
 |
|
|
|
|
 |
V.A.Streltsov,
J.A.Carmichael,
and
S.D.Nuttall
(2005).
Structure of a shark IgNAR antibody variable domain and modeling of an early-developmental isotype.
|
| |
Protein Sci, 14,
2901-2909.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
C.J.Camacho,
and
D.W.Gatchell
(2003).
Successful discrimination of protein interactions.
|
| |
Proteins, 52,
92-97.
|
 |
|
|
|
|
 |
D.S.Law,
L.F.Ten Eyck,
O.Katzenelson,
I.Tsigelny,
V.A.Roberts,
M.E.Pique,
and
J.C.Mitchell
(2003).
Finding needles in haystacks: Reranking DOT results by using shape complementarity, cluster analysis, and biological information.
|
| |
Proteins, 52,
33-40.
|
 |
|
|
|
|
 |
D.W.Ritchie
(2003).
Evaluation of protein docking predictions using Hex 3.1 in CAPRI rounds 1 and 2.
|
| |
Proteins, 52,
98.
|
 |
|
|
|
|
 |
E.Ben-Zeev,
A.Berchanski,
A.Heifetz,
B.Shapira,
and
M.Eisenstein
(2003).
Prediction of the unknown: inspiring experience with the CAPRI experiment.
|
| |
Proteins, 52,
41-46.
|
 |
|
|
|
|
 |
G.R.Smith,
and
M.J.Sternberg
(2003).
Evaluation of the 3D-Dock protein docking suite in rounds 1 and 2 of the CAPRI blind trial.
|
| |
Proteins, 52,
74-79.
|
 |
|
|
|
|
 |
J.Fernández-Recio,
M.Totrov,
and
R.Abagyan
(2003).
ICM-DISCO docking by global energy optimization with fully flexible side-chains.
|
| |
Proteins, 52,
113-117.
|
 |
|
|
|
|
 |
J.Janin,
and
B.Séraphin
(2003).
Genome-wide studies of protein-protein interaction.
|
| |
Curr Opin Struct Biol, 13,
383-388.
|
 |
|
|
|
|
 |
L.J.Holt,
C.Herring,
L.S.Jespers,
B.P.Woolven,
and
I.M.Tomlinson
(2003).
Domain antibodies: proteins for therapy.
|
| |
Trends Biotechnol, 21,
484-490.
|
 |
|
|
|
|
 |
L.Krippahl,
J.J.Moura,
and
P.N.Palma
(2003).
Modeling protein complexes with BiGGER.
|
| |
Proteins, 52,
19-23.
|
 |
|
|
|
|
 |
P.W.Fitzjohn,
and
P.A.Bates
(2003).
Guided docking: first step to locate potential binding sites.
|
| |
Proteins, 52,
28-32.
|
 |
|
|
|
|
 |
R.Méndez,
R.Leplae,
L.De Maria,
and
S.J.Wodak
(2003).
Assessment of blind predictions of protein-protein interactions: current status of docking methods.
|
| |
Proteins, 52,
51-67.
|
 |
|
|
|
|
 |
S.D.Nuttall,
U.V.Krishnan,
L.Doughty,
K.Pearson,
M.T.Ryan,
N.J.Hoogenraad,
M.Hattarki,
J.A.Carmichael,
R.A.Irving,
and
P.J.Hudson
(2003).
Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70.
|
| |
Eur J Biochem, 270,
3543-3554.
|
 |
|
|
|
|
 |
V.Joosten,
C.Lokman,
C.A.Van Den Hondel,
and
P.J.Punt
(2003).
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.
|
| |
Microb Cell Fact, 2,
1.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|